Breaking News

Agilent, Seoul University To Establish New Research Center

May 13, 2014

Will provide drug development from identification through to clinical trial testing

Agilent Technologies, Inc. has entered a collaboration with Seoul National University for a new research center that will support the College of Pharmacy’s New Drug Development Center. The collaboration will conduct drug metabolism studies and research to evaluate and develop new compounds, as well as assess toxicity and pharmacokinetics, and conduct clinical tests for drugs.
 
Agilent will provide bioanalytical instruments and expertise for drug testing and multi-omic biological systems. The jointly established research center will also serve as Agilent’s reference site for drug development. This new multi-purpose research center will house facilities for analysis, efficacy testing, medicinal ingredient research, as well as a medicinal chemistry lab.
 
“One of the megatrends fueling life science research is the aging population,” said Agilent’s Rod Minett, general manager, Life Sciences, South Korea and South Asia-Pacific region. “Through continual research, trials and developments, we believe that newer, more effective drugs can be developed. As such, Agilent is pleased to support SNU College of Pharmacy’s drive to create better drugs for a safer and healthier population.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent